CSS
LRMR icon

Cubist Systematic Strategies’s Larimar Therapeutics LRMR Stock Holding History

Cubist Systematic Strategies’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$524K Buy
+162,159
New +$608K ﹤0.01% 2263
2025
Q2 		– Sell
-354,232
Closed -$762K – 3299
2025
Q1 		$762K Buy
354,232
+120,359
+51% +$380K ﹤0.01% 1961
2024
Q4 		$905K Buy
233,873
+172,131
+279% +$1.14M 0.01% 1853
2024
Q3 		$404K Buy
61,742
+61,357
+15,937% +$493K ﹤0.01% 2292
2024
Q2 		$2.79K Sell
385
-21,702
-98% -$166K ﹤0.01% 2838
2024
Q1 		$168K Buy
+22,087
New +$172K ﹤0.01% 3144
2023
Q2 		– Sell
-17,421
Closed -$78.9K – 3966
2023
Q1 		$78.9K Buy
17,421
+10,388
+148% +$54.3K ﹤0.01% 3481
2022
Q4 		$29K Sell
7,033
-23,022
-77% -$78.6K ﹤0.01% 3966
2022
Q3 		$96K Buy
+30,055
New +$75.3K ﹤0.01% 4029
2021
Q4 		– Sell
-793
Closed -$9K – 3549
2021
Q3 		$9K Sell
793
-2,457
-76% -$29.5K ﹤0.01% 2909
2021
Q2 		$32K Buy
3,250
+1,429
+78% +$16.1K ﹤0.01% 2825
2021
Q1 		$27K Buy
+1,821
New +$33.1K ﹤0.01% 2761
2020
Q4 		– Sell
-709
Closed -$11K – 2645
2020
Q3 		$11K Buy
+709
New +$8.98K ﹤0.01% 2428
2020
Q2 		– Sell
-282
Closed -$3K – 2472
2020
Q1 		$3K Sell
282
-69
-20% -$907 ﹤0.01% 2107
2019
Q4 		$5K Buy
+351
New +$3.35K ﹤0.01% 2379
2019
Q2 		– Sell
-1,724
Closed -$57K – 2525
2019
Q1 		$57K Sell
1,724
-274
-14% -$14K ﹤0.01% 2086
2018
Q4 		$119K Buy
1,998
+1,383
+225% +$137K 0.01% 1726
2018
Q3 		$86K Buy
+615
New +$74.7K ﹤0.01% 1631
2016
Q3 		– Sell
-2,092
Closed -$150K – 1783
2016
Q2 		$150K Sell
2,092
-555
-21% -$43.9K 0.01% 1424
2016
Q1 		$212K Sell
2,647
-5,184
-66% -$409K 0.01% 1188
2015
Q4 		$591K Buy
+7,831
New +$1.26M 0.03% 735
2015
Q2 		– Sell
-57
Closed -$27K – 1943
2015
Q1 		$27K Buy
+57
New +$27.1K ﹤0.01% 1807

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Cubist Systematic Strategies's LRMR Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Larimar Therapeutics (LRMR) in Q3 2025: 162,159 shares worth $524K. The stake represents ﹤0.01% of the portfolio and ranks #2263 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in LRMR as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in LRMR in Q1 2015 and has held it in 22 quarters since. The position peaked at $905K in Q4 2024. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

  • Cubist Systematic Strategies held 162,159 shares of Larimar Therapeutics worth $524K as of Q3 2025.
  • Larimar Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Larimar Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2263 holding.
  • Cubist Systematic Strategies first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 22 quarters since.
  • Cubist Systematic Strategies's Larimar Therapeutics position peaked at $905K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.